Page last updated: 2024-11-06

2,2'-dithiodiethanesulfonic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

2,2'-Dithiodiethanesulfonic acid (also known as DTE, or sodium dithiodiethanesulfonate) is a powerful reducing agent that is used in a variety of applications, including biochemistry, analytical chemistry, and environmental science. It is a water-soluble compound that is typically synthesized by the reaction of ethanethiol with sulfur dioxide in the presence of a base. DTE is a strong reductant that can reduce a wide range of compounds, including disulfide bonds, metal ions, and organic compounds. It is particularly effective at reducing disulfide bonds, which are found in proteins and other biological molecules. DTE's ability to reduce disulfide bonds makes it a valuable tool for studying protein structure and function. It is also used as an antioxidant, as it can scavenge free radicals. DTE has been used in a variety of environmental applications, such as the treatment of wastewater and the removal of heavy metals. It is also being investigated as a potential treatment for a variety of diseases, including cancer and Alzheimer's disease. DTE is a highly versatile compound with a wide range of applications. Its ability to reduce disulfide bonds and other compounds makes it a valuable tool for researchers and scientists in a variety of disciplines. '

Cross-References

ID SourceID
PubMed CID65626
CHEMBL ID2009034
SCHEMBL ID773704
MeSH IDM0088193

Synonyms (31)

Synonym
ethanesulfonic acid, 2,2'-dithiobis-
45127-11-5
2,2'-dithiodiethanesulfonic acid
2-(2-sulfoethyldisulfanyl)ethanesulfonic acid
2,2'-dithiodiethanesulfonic acid;coenzyme
A26305
coenzyme m disulfide
C19637
(s-com)2
2,2'-disulfanediyldiethanesulfonic acid
omega,omega'-ethanedisulfidedisulfonic acid
6q2l2h0pof ,
2,2'-dithidi-1-ethanesulfonic acid
bis(2-sulfoethyl)disulfide
unii-6q2l2h0pof
AKOS016002982
FT-0603772
BYUKOOOZTSTOOH-UHFFFAOYSA-N
2,2'-dithiobis ethane sulfonic acid
SCHEMBL773704
CHEMBL2009034
.omega.,.omega.'-ethanedisulfidedisulfonic acid
dimesna free acid
mesna impurity d [ep impurity]
J-506838
DTXSID40196395
(2,2-(disulfane diyl)bis(ethanesulphonic acid)
2,2-(disulfane diyl)bis(ethanesulphonic acid)
AMY10917
Q27265315
mesna impurity d

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" mesna administration, the mean half-life of mesna was 21."( Pharmacokinetics of intravenous and oral sodium 2-mercaptoethane sulphonate (mesna) in normal subjects.
James, CA; Mant, TG; Rogers, HJ, 1987
)
0.27
" We also evaluated potential pharmacokinetic interactions between BNP7787 and cisplatin."( Pharmacokinetics of BNP7787 and its metabolite mesna in plasma and ascites: a case report.
Boven, E; Hausheer, FH; Van der Vijgh, WJ; Verschraagen, M; Zegers, I, 2003
)
0.32
" For pharmacokinetic investigation of BNP7787 and mesna and a possible mutual pharmacokinetic interaction between BNP7787 and cisplatin, cisplatin and BNP7787 were also administered as single agents in 14 of 25 patients."( Pharmacokinetics and preliminary clinical data of the novel chemoprotectant BNP7787 and cisplatin and their metabolites.
Berkhof, J; Boven, E; Hausheer, FH; Ruijter, R; van der Born, K; van der Vijgh, WJ; Verschraagen, M, 2003
)
0.32
" The pharmacokinetic profile of mesna was unaffected by cisplatin and its metabolites."( Pharmacokinetics and preliminary clinical data of the novel chemoprotectant BNP7787 and cisplatin and their metabolites.
Berkhof, J; Boven, E; Hausheer, FH; Ruijter, R; van der Born, K; van der Vijgh, WJ; Verschraagen, M, 2003
)
0.32
" The combination of BNP7787 with cisplatin did not alter the pharmacokinetic profiles of mesna or the cisplatin metabolites."( Pharmacokinetics and preliminary clinical data of the novel chemoprotectant BNP7787 and cisplatin and their metabolites.
Berkhof, J; Boven, E; Hausheer, FH; Ruijter, R; van der Born, K; van der Vijgh, WJ; Verschraagen, M, 2003
)
0.32

Dosage Studied

ExcerptRelevanceReference
" Following oral mesna dosing the mean peak mesna concentration was 19."( Pharmacokinetics of intravenous and oral sodium 2-mercaptoethane sulphonate (mesna) in normal subjects.
James, CA; Mant, TG; Rogers, HJ, 1987
)
0.27
"3 mmol/l) displaces the dose-response curve for acrolein to the left, indicating an increased toxicity of the combination of acrolein plus Dimesna."( Ifosfamide and mesna: effects on the Na/H exchanger activity in renal epithelial cells in culture (LLC-PK1).
Brandis, M; Küpper, N; Mohrmann, M; Schönfield, B,
)
0.13
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (56)

TimeframeStudies, This Drug (%)All Drugs %
pre-199018 (32.14)18.7374
1990's10 (17.86)18.2507
2000's18 (32.14)29.6817
2010's10 (17.86)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.19

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.19 (24.57)
Research Supply Index4.22 (2.92)
Research Growth Index4.41 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.19)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials9 (15.52%)5.53%
Reviews5 (8.62%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other44 (75.86%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (3)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Phase II Randomized Study Of Dose-Dense Docetaxel And Cisplatin Every Two Weeks With Pegfilgrastim And Darbepoetin Alfa With And Without The Chemoprotector BNP7787 In Patients With Advanced Non-Small Cell Lung Cancer [NCT00077311]Phase 2160 participants (Actual)Interventional2004-08-31Completed
BNP7787 vs. Placebo for Prevention of Paclitaxel Neurotoxicity: A Double-Blind Multicenter Randomized Phase 3 Trial in Patients With Metastatic Breast Cancer [NCT00039780]Phase 3764 participants (Actual)Interventional2001-09-30Completed
Randomized, Multicenter, Double-blind, Phase 3 Trial of Tavocept Versus Placebo in Patients With Newly Diagnosed or Relapsed Advanced Primary Adenocarcinoma of the Lung Treated With Docetaxel or Paclitaxel Plus Cisplatin [NCT00966914]Phase 3540 participants (Actual)Interventional2010-04-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]